ACM Biolabs

About:

ACM Biolabs develops novel vaccines and antibodies using proprietary artificial cell membrane technology.

Top Investors: Ritz Venture Capital

Description:

ACM Biolabs focuses on developing novel vaccines and antibodies using proprietary artificial cell membrane ("ACM") technology. ACM is able to incorporate functional, folded membrane proteins into the artificial cell membranes which keeps them stable, allowing them to induce a strong immune reaction. ACM has demonstrated efficacy via both injected and oral dosages using synthesized membrane proteins and has a growing pipeline of vaccines and antibodies. The company is headquartered in Singapore, and has been operational since 2013.

Total Funding Amount:

$6.8M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Singapore, Central Region, Singapore

Founded Date:

2013-01-01

Contact Email:

office(AT)acmbiolabs.com

Founders:

Madhavan Nallani

Number of Employees:

11-50

Last Funding Date:

2022-09-19

IPO Status:

Private

Industries: